BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36675491)

  • 1. PFC@O
    Lan Z; Zou KL; Cui H; Chen H; Zhao YY; Yu GT
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Radiochemotherapy Alters the Immune and Metabolic Microenvironment in Oral Cancer-Analyses of CD68, CD163, TGF-β1, GLUT-1 and HIF-1α Expressions.
    Weber M; Ries J; Braun K; Wehrhan F; Distel L; Geppert C; Lutz R; Kesting M; Trumet L
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiated embryo chondrocyte 1, induced by hypoxia-inducible factor 1α, promotes cell migration in oral squamous cell carcinoma cell lines.
    Yang L; Zeng L; Wang Z; Hu X; Xiong H; Zhang T; Chen W; Xia K; Su T
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Feb; 133(2):199-206. PubMed ID: 34758939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced anti-tumor efficacy by inhibiting HIF-1α to reprogram TAMs
    Zhang LJ; Huang R; Shen YW; Liu J; Wu Y; Jin JM; Zhang H; Sun Y; Chen HZ; Luan X
    Biomater Sci; 2021 Sep; 9(19):6403-6415. PubMed ID: 34259235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief.
    Jiang M; Qin B; Luo L; Li X; Shi Y; Zhang J; Luo Z; Zhu C; Guan G; Du Y; You J
    J Control Release; 2021 Jul; 335():408-419. PubMed ID: 34089792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between cancer and different cancer stroma subtypes promotes the infiltration of tumor‑associated macrophages into the tumor microenvironment of oral squamous cell carcinoma.
    Shan Q; Takabatake K; Kawai H; Oo MW; Sukegawa S; Fujii M; Nakano K; Nagatsuka H
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35514301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltration of m2 tumor-associated macrophages in oral squamous cell carcinoma correlates with tumor malignancy.
    Mori K; Hiroi M; Shimada J; Ohmori Y
    Cancers (Basel); 2011 Sep; 3(4):3726-39. PubMed ID: 24213108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the expression of TGF-β1, E-cadherin, N-cadherin, TP53, RB1CC1 and HIF-1α in oral squamous cell carcinoma and lymph node metastases of humans and mice.
    Guo M; Mu Y; Yu D; Li J; Chen F; Wei B; Bi S; Yu J; Liang F
    Oncol Lett; 2018 Feb; 15(2):1639-1645. PubMed ID: 29399192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mucoadhesive celecoxib-loaded cubosomal sponges: Anticancer potential and regulation of myeloid-derived suppressor cells in oral squamous cell carcinoma.
    Mabrouk AA; El-Mezayen NS; Tadros MI; El-Gazayerly ON; El-Refaie WM
    Eur J Pharm Biopharm; 2023 Jan; 182():62-80. PubMed ID: 36513316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression.
    Suárez-Sánchez FJ; Lequerica-Fernández P; Suárez-Canto J; Rodrigo JP; Rodriguez-Santamarta T; Domínguez-Iglesias F; García-Pedrero JM; de Vicente JC
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
    Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
    Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
    Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
    Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
    Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
    J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-18a regulates the metastatic properties of oral squamous cell carcinoma cells via HIF-1α expression.
    Kim S; Park S; Oh JH; Lee SS; Lee Y; Choi J
    BMC Oral Health; 2022 Sep; 22(1):378. PubMed ID: 36064348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
    Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
    Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells.
    Sasabe E; Zhou X; Li D; Oku N; Yamamoto T; Osaki T
    Int J Cancer; 2007 Jan; 120(2):268-77. PubMed ID: 17066447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.